ATRS
Undervalued by 6.9% based on the discounted cash flow analysis.
Market cap | $0.00 |
---|---|
Enterprise Value | $-42,822,000.00 |
Dividend Yield | $0 (0%) |
Earnings per Share | $0.27 |
Beta | 1.15 |
Outstanding Shares | 170,104,000 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 20.55 |
---|---|
PEG | -12.75 |
Price to Sales | 5.59 |
Price to Book Ratio | 5.59 |
Enterprise Value to Revenue | -0.23 |
Enterprise Value to EBIT | -2.24 |
Enterprise Value to Net Income | -2 |
Total Debt to Enterprise | -0.45 |
Debt to Equity | 0.11 |
No data
No data
Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Com...